![]() ![]() As a result, the company is cutting its staff by 45%, primarily those in "research and supportive functions." 14, 2022: Harpoon Therapeutics: Harpoon is releasing a number of preclinical projects back into the ocean to focus time and resources on ongoing clinical assets. The company has also retained a couple of advisors to help find an escape hatch, likely in the former of a sale or merger. 14, 2022: Tricidia: With the corporate walls seemingly closing in quickly on Tricidia, the company is trimming its staff by more than half to stay afloat. Instead, the company says its pivoting to focus on its AIM INJ injectable immunotherapy. 14, 2022: NexImmune: With its eyes set on new pipeline priorities, NexImmune is laying off 30% of its staff, primarily those working on its once-lead AIM ACT program. The company says it will have roughly 100 employees by the end of the year. 15, 2022: Freeline Therapeutics: In order to prevent a financial freefall, Freeline Therapeutics has reduced its workforce by roughly 23%, or 30 employees. Rafael expects to incur severance charges of about $500,000. 15, 2022: Rafael Holdings: The New Jersey company is laying off "under 10" employees, a spokesperson for Rafael told Fierce Biotech. That equates to 105 layoffs, according to a WARN notice filed Nov. 18, 2022: Synthego: After a comprehensive review, the company has implemented changes "to best position the company for long-term success in the current environment," including a 20% workforce reduction, a spokesperson told Fierce Biotech via email. A recent 75% reduction in its R&D workforce was prompted by a complete response letter from the FDA that provided the final nail in the coffin for Spectrum's lung cancer candidate Pozenveo. 25, 2022: Spectrum Pharmaceuticals: The biotech is ending the year as it started it-with a round of layoffs. 29, 2022: Sana Biotechnology: The Seattle-based biotech is letting go of 15% of its workforce and discontinuing development of a heart failure drug.The pared-back workforce and investment strategy is hoped to provide a cash runway over the next several years. 29, 2022: Codexis: The enzyme engineering company is laying off 18% of staff, which would equate to about 59 employees based on the company’s 329 staff members listed on LinkedIn. 30, 2022: Oncorus: The biotech has dropped its phase 1 herpes simplex virus drug being studied combination with Keytruda in solid tumors, a piipeline cull that triggered a 20% workforce reduction. The remaining employees will focus on developing a self-amplifying RNA product candidate dubbed ONCR-021. ![]() 30, 2022: Synlogic: Along with pipeline culls, the synthetic biology company is slimming its workforce by 25%. The Massachusetts biotech lists 93 employees on LinkedIn, meaning a quarter cull would equate to about 23 people. The company anticipates the cost-saving measures to extend the biotech’s cash runway into 2024. 30, 2022: SQZ Biotechnologies: As the biotech's CEO hits the exits, the company has announced a 60% staff reduction in tandem with a pipeline restructure. The smaller biotech says it will first cut staff tied to zandelisib development, representing at least 30% of the total workforce, but did not count out additional cuts to save more cash. 6, 2022: MEI Pharma: Layoffs are hitting MEI Pharma after the company elected to discontinue ex-Japan development of its Kyowa Kirin-partnered lymphoma med, zandelisib. 8, 2022: Instil Bio: The biotech is calling it quits on its lead tumor-infiltrating lymphocyte therapy, a major overhaul that’s resulting in 60% of its staff getting laid off. All told, 85% of the company was laid off.ĭec. 15, 2022: Axcella: Almost all of the Axcella team is headed for the exits after the company ended work of its NASH program to focus on developing a long COVID therapy. ![]() ![]() 'Stay alive': Wave of layoffs crashes into biotech startup inferno December -3 companies totalĭec. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |